Document Detail


Medical treatment of glaucoma: present and future.
MedLine Citation:
PMID:  21534887     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: In the last decades, the therapy of glaucoma has largely shifted from surgery to medical treatment thanks to the introduction of strongly effective formulations, that is, prostaglandin analogs and fixed combinations. This clinical scenario may dramatically change in the future thanks to the progresses in biochemistry, genetics and drug delivery technology.
AREAS COVERED: This review covers the strategies currently used to achieve effective medical reduction of intraocular pressure in clinical practice; treatments that are currently been experimented in humans and that may be clinically available in the next few years; treatments at preclinical stages; and future goals of glaucoma treatment (gene therapy, ocular implants and neuroprotection).
EXPERT OPINION: Apart from an adequate reduction of intraocular pressure, effective glaucoma treatments should guarantee other characteristics: good tolerability, low problems of adherence and, possibly, multiple ways of action. From this viewpoint, a crucial clinical role may be played by drugs remodeling the trabecular meshwork (i.e., ROCK inhibitors, metalloproteinases). Other strategies such as the use of ocular implants for drug delivery, neuroprotection or gene therapy could renew glaucoma management in the future, but need long-term rigorous verification of safety and efficacy.
Authors:
Paolo Fogagnolo; Luca Rossetti
Related Documents :
12084497 - Once daily sustained release tablets of venlafaxine, a novel antidepressant.
14705187 - Release kinetics of catechins from chewing gum.
10613927 - Modeling of drug release from swellable polymers.
19604137 - Sustained release of diltiazem hydrochloride from chitosan micro-capsules.
24907737 - Preparation of keratin hydrogel/hydroxyapatite composite and its evaluation as a contro...
20809897 - Pathway-specific, species, and sub-type counterscreening for better gpcr hits in high t...
Publication Detail:
Type:  Journal Article; Review     Date:  2011-05-03
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  20     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-06-13     Completed Date:  2012-05-07     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  947-59     Citation Subset:  IM    
Affiliation:
G. B. Bietti Foundation - IRCC, Rome, Italy. fogagnolopaolo@googlemail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antihypertensive Agents / administration & dosage,  metabolism
Glaucoma / drug therapy*,  metabolism,  surgery*
Humans
Intraocular Pressure / drug effects,  physiology
Neuroprotective Agents / administration & dosage,  metabolism
Ophthalmic Solutions / administration & dosage,  metabolism
Predictive Value of Tests
Prostaglandins / administration & dosage,  metabolism
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Neuroprotective Agents; 0/Ophthalmic Solutions; 0/Prostaglandins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antiretroviral use during pregnancy for treatment or prophylaxis.
Next Document:  Volatile and lipid analyses by gas chromatography/mass spectrometry and nutraceutical potential of e...